Graftys announced that one of its strategic projects has been granted a U.S. patent to have new osteogenic calcium phosphate cement (CPC) technology combined with autologous whole blood tissue.
Responding to a medical need and to a direct request from orthopedic surgeons, a new generation of macroporous CPC allows surgeons to target new emerging applications such as deep cavity filling. Through its advanced plasticity and high cohesiveness, this new biomaterial is composed of a 3D continuous organic network of fibrin entangled within a microstructure of large platelet-like apatite crystals.
Based on blood clotting processing, this new macroporous BioCPC is designed to stimulate bone regeneration with tremendous healing properties.
Sébastien Genesta, Managing Director, said, “We are very proud to have our CPC technology expand beyond its current indication. The approval of this patent allows us to continue to research more unmet clinical needs in the orthobiologics sector. We further aim to reach global patents in Europe and Japan.”
Graftys announced that one of its strategic projects has been granted a U.S. patent to have new osteogenic calcium phosphate cement (CPC) technology combined with autologous whole blood tissue.
Responding to a medical need and to a direct request from orthopedic surgeons, a new generation of macroporous CPC allows surgeons to target new emerging...
Graftys announced that one of its strategic projects has been granted a U.S. patent to have new osteogenic calcium phosphate cement (CPC) technology combined with autologous whole blood tissue.
Responding to a medical need and to a direct request from orthopedic surgeons, a new generation of macroporous CPC allows surgeons to target new emerging applications such as deep cavity filling. Through its advanced plasticity and high cohesiveness, this new biomaterial is composed of a 3D continuous organic network of fibrin entangled within a microstructure of large platelet-like apatite crystals.
Based on blood clotting processing, this new macroporous BioCPC is designed to stimulate bone regeneration with tremendous healing properties.
Sébastien Genesta, Managing Director, said, “We are very proud to have our CPC technology expand beyond its current indication. The approval of this patent allows us to continue to research more unmet clinical needs in the orthobiologics sector. We further aim to reach global patents in Europe and Japan.”
Copy to clipboard 
